$TLSI

TriSalus Life Sciences (TLSI) will present new clinical and preclinical data at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The presentations will highlight the capabilities of its Pressure Enabled Drug Delivery (PEDD) platform for applications in liver-directed therapies and uterine artery embolization, demonstrating the platform's versatility in enhancing therapeutic delivery across various disease states. The company's CEO, Mary Szela, and CMO, Richard Marshall, emphasized the growing body of evidence supporting PEDD's potential to improve patient outcomes by enabling more effective delivery of therapies.